Maternal glycaemic control and risk of neonatal hypoglycaemia in Type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial

Yamamoto, Jennifer, Corcoy, Rosa, Donovan, Lois E., Stewart, Zoe A., Beardsall, Kathryn, Feig, Denice S. and Murphy, Helen and The CONCEPTT Collaborative Group (2019) Maternal glycaemic control and risk of neonatal hypoglycaemia in Type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial. Diabetic Medicine: a journal of the British Diabetic Association, 36 (8). pp. 1046-1053. ISSN 0742-3071

[thumbnail of Accepted_Manuscript]
Preview
PDF (Accepted_Manuscript) - Accepted Version
Download (769kB) | Preview
[thumbnail of Yamamoto_et_al-2019-Diabetic_Medicine]
Preview
PDF (Yamamoto_et_al-2019-Diabetic_Medicine) - Accepted Version
Download (700kB) | Preview

Abstract

Aims: To examine the relationship between maternal glycaemic control and risk of neonatal hypoglycaemia using conventional and continuous glucose monitoring (CGM) metrics in the Continuous Glucose Monitoring in Type 1 Diabetes Pregnancy Trial (CONCEPTT) participants. Methods: A secondary analysis of CONCEPTT involving 225 pregnant women and their liveborn infants. Antenatal glycaemia was assessed at 12, 24 and 34 weeks gestation. Intrapartum glycaemia was assessed by CGM measures 24 hours prior to delivery. The primary outcome was neonatal hypoglycaemia defined as glucose concentration <2.6 mmol/L and requiring intravenous dextrose. Results: Neonatal hypoglycaemia occurred in 57/225 (25.3%) infants; 21 (15%) term and 36 (40%) preterm neonates. During the second and third trimesters, mothers of infants with neonatal hypoglycaemia had higher HbA1c (487 [6.6±0.6] vs 45± 7 [6.2±0.6]; p=0.0009 and 50 ±7 [6.7±0.6] vs 46 ± 7 [ 6.3±0.6]; p=0.0001) and lower CGM time-in-range (45.9% vs 53.0%; p=0.004 and 60.1% vs 65.7%; p=0.03). Neonates with hypoglycaemia had higher cord blood C-peptide (1416 [834, 2757] vs 662 [417, 1086] pmol/L; p<0.00001), birthweight >97.7th centile (63.2% vs 33.9%; p<0.0001) and skinfold thickness (p≤0.02). Intrapartum CGM was available for 33 participants, with no differences between mothers of neonates with and without hypoglycaemia. Conclusions: Modest increments in CGM time-in-target (5-7% increase) during the second and third trimesters are associated with reduced risk for neonatal hypoglycaemia. While more intrapartum CGM data are needed, the higher birthweight and skinfold measures associated with neonatal hypoglycaemia, suggest that risk is related to fetal hyperinsulinemia preceding the immediate intrapartum period.

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User: LivePure Connector
Date Deposited: 23 May 2019 09:30
Last Modified: 19 Oct 2023 02:27
URI: https://ueaeprints.uea.ac.uk/id/eprint/71105
DOI: 10.1111/dme.13988

Actions (login required)

View Item View Item